We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

XTL Biopharmaceuticals Ltd (XTLB) ADR Each Repr 100 Shs Spon

Sell:$0.89 Buy:$1.88 Change: $0.06 (3.39%)
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Sell:$0.89
Buy:$1.88
Change: $0.06 (3.39%)
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Sell:$0.89
Buy:$1.88
Change: $0.06 (3.39%)
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

XTL Biopharmaceuticals Ltd is an Israel-based biopharmaceutical company engaged in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The Company pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong the survival of patients for the treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by the kidney. EPO stimulates erythropoiesis, the production of red blood cells, by binding to its receptor on the surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.

Contact details

Address:
5 Badner St.,
P.O.Box 8241
RAMAT GAN
5218102
Israel
Telephone:
+972 (9) 9557080
Website:
https://www.xtlbio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
XTLB
ISIN:
US98386D3070
Market cap:
$22.48 million
Shares in issue:
544.91 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
Israel
Currency:
US dollar
Indices:
n/a

Key personnel

  • Shlomo Shalev
    Chief Executive Officer, Director
  • Itay Weinstein
    Chief Financial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.